$53 million deal points to lucrative marijuana market in Florida

While we missed out celebrating 4/20 with a growing number of Americans, the budding marijuana market is one managers may be wise to roll into strategies moving forward.

The demographics and realities in America are changing the perception around weed, with the realization that it is a useful, non-addictive pain management option in an increasingly medication-addicted, under-insured populace.

States and politicians are presently hashing it out, obviously eager to tap into the potential tax revenue, and gingerly tiptoeing through the moral minefield that’s been piped by government messaging for over half a century.

However it shakes out, managers are smart to consider how their own messaging portrays marijuana within the purview of their fund’s strategy. If investing in alcohol, you’re probably ready to safely add weed and its associated growing industries, along with some clear communication about how the fund defines such things.

Whatever a fund’s approach, it’s clear that the marijuana market is indeed lighting up.

A California-based company has bought a Florida medical marijuana operation for $53 million in the latest transaction in what investors hope will be among the nation’s most-lucrative medical pot markets.